



HAL
open science

Obstetrical Morbidity Related to Anti-SSA Antibodies: Data from a French Monocentric Retrospective Study

Léo Placais, Fabrice Carrat, Lionel Carbillon, Pascale Nicaise Roland, Amélie Benbara, Carlotta Cacciatore, Olivier Fain, Arsène Mekinian

► **To cite this version:**

Léo Placais, Fabrice Carrat, Lionel Carbillon, Pascale Nicaise Roland, Amélie Benbara, et al.. Obstetrical Morbidity Related to Anti-SSA Antibodies: Data from a French Monocentric Retrospective Study. *Joint Bone Spine*, 2019, 86 (4), pp.523–524. 10.1016/j.jbspin.2018.11.005 . hal-03777537

HAL Id: hal-03777537

<https://hal.sorbonne-universite.fr/hal-03777537>

Submitted on 1 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Obstetrical morbidity related to anti-SSA antibodies: data from a French monocentric retrospective study

Léo Placais^{1,2}, Fabrice Carrat^{3,4,5}, Lionel Carbillon^{6,7}, Pascale Nicaise Roland^{8,9}, Amélie Benbara^{6,7}, Carlotta Cacciatore^{1,2}, Olivier Fain^{1,2}, Arsène Mekinian^{1,2}

1 Sorbonne Universités, 75006 Paris, France

2 Service de Médecine Interne-DHU i2B, Hôpital Saint-Antoine, APHP, 75012, Paris, France.

3 Sorbonne Universités, UPMC Université 75006 Paris, France

4 INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), 75012, Paris, France;

5 Unité de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, 75012 Paris, France.

6 Service de Gynécologie Obstétrique, Hôpital Jean-Verdier, APHP, 93000, Bondy, France.

7 Université Paris 13, 9300 Bobigny

8 Service d'Auto-immunité Hypersensibilité, Hôpital Bichat, APHP, 75017, Paris, France

9 Université Paris 7, 78018 Paris, France

Correspondance and reprints to Arsène Mekinian, AP-HP, Hôpital Saint-Antoine, service de Médecine Interne-(DHU i2B), Université Paris 06, 184 rue du faubourg Saint Antoine, 75012, Paris, France, arsene.mekinian@aphp.fr

Keywords: obstetrical morbidity, anti-SSA antibodies, hydroxychloroquine, aspirin.

Anti-SSA/Ro autoantibodies can be found in several connective-tissue diseases. Their impact on obstetrical outcomes other than congenital heart block is controversial, and was mainly explored in women with connective tissue diseases [1; 2; 3]. However, anti-SSA positivity in women with recurrent unexplained adverse obstetrical events has not been assessed. Here, we report a French monocentric study of women with unexplained adverse obstetrical outcomes and the prevalence and impact of anti-SSA/Ro antibodies on the obstetrical outcome.

We retrospectively included all patients consulting for obstetrical morbidity (early recurrent miscarriage, intrauterine death; intra-uterine growth restriction; preeclampsia, eclampsia prematurity) in the absence of known etiology from 2011 to 2015 (244 women, median age 34 years [IQR 21-53]) and recorded 869 pathological pregnancies over the 12,250 followed in this center [Appendix A, Figure S1; See the supplementary material associated with this article online]. All patients underwent testing for anti-nuclear antibodies, anti-SSA/Ro and anti-SSB/La antibodies, antiphospholipid and antithyroid antibodies at pre-conception visit.

A total of 27/244 women (11%) had anti-SSA antibodies (4 had both anti-SSA and anti-SSB antibodies); among them, diagnosis of primary Sjogren's syndrome (pSS) was made in 8 cases and 19 were asymptomatic anti-SSA antibodies carriers. In the anti-SSA carrying subgroup, median age was 29.5 [IQR 17-40] years, with a mean number of 3.66 pregnancies/ woman. Eighty three of the 99 pregnancies (84%) had an adverse outcome: 65 fetal losses, 15 preeclampsia, 7 IUGR, 7 prematurity, 2 congenital heart blocks. Women with pSS (n=8; 31 pregnancies) and asymptomatic anti-SSA carriage (n=19; 68 pregnancies) had similar rates of fetal death and miscarriage, but were more often treated (55% vs 30%) (Appendix A, **Table 1**). Treatment was initiated during pregnancy for 38/99 pregnancies in women with anti-SSA antibodies and consisted in low-dose aspirin (n=34), low-molecular-weight heparin (LMWH, n=21), hydroxychloroquine (n=18), low-dose steroids (n=18) and other agents (n=5; intravenous immunoglobulins, rituximab, eculizumab). Among asymptomatic anti-SSA carriers, treatment decreased fetal losses from 85% to 25% (OR 0.06 [95% CI 0.01; 0.39]; p=0.003). A similar effect was found in women with confirmed Sjogren's syndrome (OR 0.22 [95% CI 0.06; 0.83]; p=0.02). Low-dose aspirin and hydroxychloroquine were significantly associated with a favorable obstetrical outcome and reduced fetal loss: OR 0.05 [95% CI 0.01; 0.37] (p=0.003) and 0.15 [0.02; 0.98] (p=0.04) (**Table 2**). Considering various adverse obstetrical complications separately, no factor was significantly associated on univariate analysis (data not shown). Among

women with unexplained obstetrical morbidity, 139 (27.2%) treated pregnancies (low dose aspirin and LMWH combination) resulted in 101 (72%) live births, whereas 371 untreated pregnancies led to 128 live births (34.6%). The prevalence of asymptomatic anti-SSA carriage in women with adverse obstetrical events history was elevated compared to general population (11% versus 0.2% [4]), but there were no significant differences in the obstetrical phenotype when compared to the obstetrical APS and to the unexplained adverse obstetrical events subgroups (**Table S1**).

Treatment with low-dose aspirin and hydroxychloroquine strongly improved the obstetrical outcome in anti-SSA antibodies carriers. Hydroxychloroquine has been shown to be safe [5], to prevent anti-SSA antibodies cardiac foetotoxicity [6] and its efficacy could be raised for anti-SSA antibodies-related obstetrical complications.

Conflicts of interest and fundings: none

Appendix A. Supplementary data

Supplementary data (Figure S1, Table S1) associated with this article can be found in the online version at ...

References

1. Brucato A, A Doria, M Frassi, G Castellino, F Franceschini, D Faden et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. *Lupus*. 2002;11:716-21.
2. Haga HJ, Gjesdal CG, Koksvik HS, Skomsvoll JF, Irgens LM, Ostensen M. Pregnancy outcome in patients with primary Sjögren's syndrome: a prospective controlled study. *J Rheumatol* 2005;32:17-34-6
3. Priori R, Gattamelata A, Modesti M, Colafrancesco S, Frisenda S, Minniti A et al. Outcome of pregnancy in Italian patients with primary Sjögren syndrome. *J Rheumatol*. 2013;40:1143-7.
4. De Vlam K, De Keyser F, Verbruggen G, Vandenbossche M, Vanneuville B, D'Haese D et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. *Clin Exp Rheumatol* 1993; 11: 393-7.
5. Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. *Autoimmun Rev*. 2005;4:111-5.
6. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. *Circulation*. 2012;126:76-82.

Table 1. Adverse obstetrical outcomes in women with isolated anti-SSA antibodies and primary Sjögren’s syndrome.

Characteristics	Isolated anti-SSA antibodies n=19 (68 pregnancies)	Primary Sjögren’s syndrome n=8 (31 pregnancies)
Miscarriages, n (%)	35/68 (51.5)	15/31 (49)
Fetal loss, n (%)	44/68 (65)	20/31(64)
Intrauterine growth restriction, n (%)	5/68 (7)	1/31 (3)
Prematurity, n (%)	2/68 (3)**	4/31 (13)
Live births in untreated pregnancy, n (%)	7/48 (14.5)	3/14 (21)
Preeclampsia, n (%)	12/68 (17.6)	3/31 (10)
Treated during pregnancy, n (%)	20/68 (30)	17/31 (55)
Aspirin, n (%)	19/68 (28)	14/31 (45)
Hydroxychloroquine, n (%)	10/68 (15)	8/31 (26)
LWMH, n (%)	10/68 (15)	10/31 (32)
Prednisone, n (%)	4/68 (6)*	10/31 (32)
Live births in treated pregnancies, n (%)	15/20 (75)	8/17 (58)

***p<0.05; **p=0.07**

Table 2. Factors associated with pregnancy loss and obstetrical complications.

	Fetal loss or obstetrical complication (N=83)	No fetal loss /obstetrical complication (N=16)	Univariate OR (95% CI)	P-value	Multivariate OR (95% CI)	P-value
Age (years, at pregnancy)	29.5±5.9	29.5±5.3	0.91 (0.83 ; 1.00)	0.05	1.13 (1.03 ; 1.24)	0.009
Untreated pregnancies, n (%)	1.64±1.60	1.44±1.36	0.72 (0.54 ; 0.95)	0.02	1.68 (1.01 ; 2.79)	0.04
Sjögren syndrome, n (%)	26 (32)	5 (31)	0.57 (0.14 ; 2.32)	0.43		
Placental intervillitis, n (%)	16 (22)	1 (7)	3.73 (0.46 ; 30.4)	0.21		
Treatment, n (%)	25 (30)	13 (81)	0.09 (0.03 ; 0.27)	<0.0001		
Aspirin, n (%)	22 (27)	12 (75)	0.10 (0.03 ; 0.28)	<0.0001	0.05 (0.01 ; 0.37)	0.003
LMWH, n (%)	5 (31)	16 (19)	0.29 (0.11 ; 0.81)	0.018	2.92 (0.52 ; 16.3)	0.2
Prednisone, n (%)	3 (19)	11 (13)	0.39 (0.13 ; 1.11)	0.07		
Hydroxychloroquine, n (%)	8 (10)	10 (63)	0.05 (0.01 ; 0.18)	<0.0001	0.15 (0.02 ; 0.98)	0.04